• No results found

University of Groningen Survivorship care after testicular cancer Boer, Hindrik

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Survivorship care after testicular cancer Boer, Hindrik"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Survivorship care after testicular cancer

Boer, Hindrik

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Boer, H. (2019). Survivorship care after testicular cancer: New insights in late effects of treatment and approaches to shared-care follow-up. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Survivorship care after testicular cancer

New insights in late effects of treatment and

approaches to shared-care follow-up

H. Boer

Survivorship care after testicular cancer

New insights in late effects of treatment and

approaches to shared-care follow-up

(3)

The research presented in this thesis was conducted at the Department of Medical Oncology, University of Groningen, University Medical Center Groningen. This research project was financially supported by the Dutch Cancer Society (project number RUG 2011-5267) and the Netherlands Comprehensive Cancer Organisation.

Layout Bianca Pijl, www.pijlldesign.nl Groningen, the Netherlands Cover design Sam Maldonado, wwwanted.nl,

Amsterdam, the Netherlands Printed by Ipskamp Printing

Enschede, the Netherlands ISBN 978-94-034-1332-7 (print)

978-94-034-1331-0 (digital)

© Copyright, 2019, H. Boer, Groningen, the Netherlands

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the author, or when appropriate, of the publishers of the publications included in this thesis.

The printing of this thesis was financially supported by the Stichting Werkgroep Interne Oncologie and the Graduate School of Medicals Science University of Groningen, University Medical Center Groningen and is gratefully acknowledged.

(4)

Survivorship care after testicular cancer

New insights in late effects of treatment and

approaches to shared-care follow-up

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. E. Sterken

en volgens besluit van het College voor Promoties

De openbare verdediging zal plaatsvinden op

maandag 25 februari 2019 om 16.15 uur

door

Hindrik Boer

geboren op 17 december 1983 te NietapRoden

(5)

Promotores

Prof. dr. J.A. Gietema Prof. dr. S. Siesling

Copromotor

Dr. A.J. Berendsen

Beoordelingscommissie

Prof. dr. W.T.A. van der Graaf Prof. dr. G.H. de Bock Prof. dr. D.J. Touw

(6)
(7)

Paranimfen

Dr. R.R.H. van den Brom Mr. dr. F.J. Vonck

(8)

Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 Chapter 8 Chapter 9

Contents

General introduction

Long-term and late effects of germ-cell testicular cancer treatment and implications for follow-up

Journal of Clinical Oncology, 2012

Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors

Annals of Oncology, 2015

Single nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors

European Journal of Cancer, 2016

Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy

European Journal of Cancer, 2016

Easy navigating through the forest of survivorship care

Journal of Clinical Oncology, 2014

The next step in survivorship care plans: In control with an easy to use mobile application

Submitted

Shared survivorship care after testicular cancer

Submitted

Summary and future perspectives

Summary in Dutch / Nederlandse samenvatting Acknowledgements / Dankwoord 9 19 47 69 89 109 117 133 155 171 179

(9)

Referenties

GERELATEERDE DOCUMENTEN

Fossa SD, de Wit R, Roberts JT, et al: Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research

and renal parameters, and comparison of Pt exposure in groups based on serum creatinine change. Median change in highest quartile: +26 µmol/L; median change in lower three

Patients homozygous or heterozygous variant for SNP rs523349 have an odds ratio of 2.56 for the metabolic syndrome after treatment for metastatic testicular cancer compared

Metastatic TC patients with a high-risk vascular fingerprint before start of (B)EP chemotherapy developed arterial vascular events more often (19% vs. 2%).. During chemotherapy

By focusing too much on the care plan as a document summarizing the treatment we tend to forget the primary goal of a plan in general: guiding follow-up care to ensure that

We launched and made available a mobile application and the accompanying SCP generator, which can be easily used to offer survivors and their healthcare providers a clear

Therefore, we designed a survivorship care program for testicular cancer survivors to test the safety and feasibility of shared-care follow-up together with the PCP, and compared

Ideally, each cancer survivor should receive survivorship care that is adjusted to his or her diagnosis and treatment plan and personal risk profile, based on